12/4
04:01 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/13
08:11 am
ngne
Neurogene (NASDAQ:NGNE) had its price target raised by analysts at HC Wainwright from $65.00 to $70.00. They now have a "buy" rating on the stock.
High
Report
Neurogene (NASDAQ:NGNE) had its price target raised by analysts at HC Wainwright from $65.00 to $70.00. They now have a "buy" rating on the stock.
11/12
04:27 pm
ngne
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome [Yahoo! Finance]
High
Report
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome [Yahoo! Finance]
11/12
04:01 pm
ngne
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
High
Report
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
11/6
08:18 am
ngne
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
Low
Report
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
11/6
07:30 am
ngne
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Medium
Report
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
11/5
04:01 pm
ngne
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
10/31
07:19 am
ngne
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/9
10:36 am
ngne
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
High
Report
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $45.00 price target on the stock.
10/9
07:15 am
ngne
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025 [Yahoo! Finance]
Medium
Report
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025 [Yahoo! Finance]
10/9
07:00 am
ngne
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
High
Report
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
10/8
12:30 pm
ngne
Neurogene (NASDAQ:NGNE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Neurogene (NASDAQ:NGNE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/8
07:30 am
ngne
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
Medium
Report
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
10/3
04:01 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/2
03:10 pm
ngne
Neurogene (NASDAQ:NGNE) was given a new $45.00 price target on by analysts at HC Wainwright.
Low
Report
Neurogene (NASDAQ:NGNE) was given a new $45.00 price target on by analysts at HC Wainwright.
9/30
07:45 am
ngne
Aurion Biotech Expands Leadership Team, Promoting Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer [Yahoo! Finance]
Low
Report
Aurion Biotech Expands Leadership Team, Promoting Andrew Torres, Ph.D., to Chief Manufacturing Officer and Sterling Chung to Chief Regulatory & Quality Officer [Yahoo! Finance]
9/5
04:01 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)